GLP1R and type 2 diabetes mellitus: Following the 2005 Food and Drug Administration approval of exenatide for glycemic control in T2D, several glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide, dulaglutide, and semaglutide, have been introduced.